SSB 5064
In CommitteeSenate
Rare diseases adv. council
Creating an advisory council on rare diseases.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill creates a new advisory council to help Washington State better understand, diagnose, and treat rare diseases by bringing together patients, clinicians, researchers, and industry experts. The council will advise state health officials, coordinate research and outreach efforts, and recommend improvements to care and public awareness.
- Establishes an advisory council on rare diseases within the University of Washington School of Medicine to advise the Washington State Secretary of Health.
- Council includes 12 voting members representing clinicians, researchers, patients, caregivers, advocates, and industry experts, with geographic and professional diversity requirements (including east and west of the Cascades).
- Council duties include advising on research, diagnosis, treatment, and education; coordinating efforts to study rare disease incidence and access to care; and making recommendations on public awareness and a centralized state website for rare disease resources.
- Council must meet at least quarterly, self-select a chair, and submit biennial reports to the governor and legislature starting December 1, 2026.
- Defines a rare disease as one affecting fewer than 200,000 people in the U.S., consistent with federal criteria.
- Members serve three-year terms, with limits on consecutive service, and may be reimbursed for travel expenses.
Who is affected
- Patients with rare diseases and their caregivers — Patients living with rare diseases and their families/caregivers will benefit from improved access to information, coordinated care, and advocacy support through the new council's work.
- Healthcare providers, schools, and public health districts — Medical providers, schools, and public health districts will receive guidance and resources to improve diagnosis, treatment, and support for rare disease patients.
- Clinicians, researchers, and academic institutions — Researchers and clinicians specializing in rare diseases will have a formal advisory role to state leadership and opportunities to collaborate on state-level initiatives.
- Life sciences industry stakeholders — The life sciences industry will have a voice in state-level rare disease policy and may help shape research priorities and commercialization pathways for therapies.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (3)
The council includes direct patient and caregiver representation and mandates recommendations to improve education for providers and schools, which is likely to reduce diagnostic delays and improve care coordination—benefiting the most vulnerable: children and low-income patients with rare diseases who face systemic barriers to care.
HealthcarePeopleRef: Sec. 2(2)(b), Sec. 3(1)(d)The requirement to establish a centralized, publicly accessible state website for rare disease resources will improve access to critical information for patients, families, and providers—especially in rural and underserved areas where specialty care is scarce.
HealthcarePeopleRef: Sec. 3(1)(f)The council’s mandate to examine access to treatment and services for rare disease patients—including cost-effectiveness of earlier diagnosis—may lead to policy recommendations that reduce long-term healthcare costs and improve equity, particularly for Medicaid-enrolled or underinsured patients.
HealthcarePeopleRef: Sec. 3(1)(b)(ii)
Potential Concerns (3)
The bill includes two life sciences industry representatives on the 12-member council, giving concentrated private-sector influence over state health policy recommendations—though the council is advisory only, its recommendations may shape research funding and commercialization priorities in ways that favor industry interests.
Business & EmploymentRef: Sec. 2(2)(e)While the University of Washington provides staff support, the bill does not guarantee permanent or dedicated funding for this support, meaning future legislative appropriations could shift costs to other state agencies or leave the council under-resourced—potentially undermining its effectiveness without clear benefit to everyday residents.
Local GovernmentRef: Sec. 2(6)The council is explicitly barred from superseding local health jurisdictions during rare disease outbreaks, but this limitation may delay or complicate coordinated responses if a rare disease has infectious components—though this is speculative, as most rare diseases are non-communicable.
Public SafetyLean peopleRef: Sec. 3(2)
Who Is Most Affected
Patients and families with rare diseases—especially children and those in rural or low-income communities—will benefit from improved access to information, reduced diagnostic delays, and coordinated care support. The council’s patient/caregiver representation ensures lived experience informs policy.
Healthcare providers and public health districts will gain access to evidence-based guidance and resources, but implementation may require additional training and infrastructure—especially in underserved regions. The benefit is positive but conditional on adequate state support.
Clinicians and researchers gain a formal platform to influence state health policy and expand collaborative research, but the advisory nature limits direct power. Academic institutions may benefit from increased visibility and potential research partnerships.
Life sciences industry representatives gain direct access to state policy discussions and may help shape research priorities and commercialization pathways—though the council’s advisory role limits direct financial gain. The benefit is positive but constrained by transparency and public accountability requirements.
State and local governments benefit from improved data collection and policy recommendations, but may face future budget pressures if the council’s recommendations lead to new mandates or programs without dedicated funding.